Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01210066 · ClinicalTrials.gov registry record · Phase 1
Pain, Opioids and Pro-Inflammatory Immune Responses
A Phase 1 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01210066: Clinical Trial Phase 1 study, sponsored by University of California, Los Angeles.
NCT01210066 is a Phase 1 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01210066, a Phase 1 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Providing pain management to the patient who abuses prescription opioids presents a clinical challenge, not only due to concerns about "drug-seeking", but because they have increased sensitivity to pain, a phenomenon identified as opioid-induced hyperalgesia (OIH). In an effort to improve pain treatment, the aims of the proposed work are to evaluate the analgesic and hyperalgesic effects of opioids to acute pain in this vulnerable population, and to examine the role of opioid-induced proinflammatory changes in these responses.
Primary Outcome
inflammatory cytokine activity will be evaluated with an in vivo approach over a three hour period of time to enable observation of the duration of opioid activity
Interventions
- OTHER Cold pressor test
- DRUG Fentanyl
- OTHER Fentanyl plus cold pressor test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Why NCT01210066 stopped before completion
NCT01210066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 3 interventions - of which Cold pressor test is the first listed.
NCT01210066 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01210066 about?
NCT01210066 is a clinical study titled "Pain, Opioids and Pro-Inflammatory Immune Responses". Providing pain management to the patient who abuses prescription opioids presents a clinical challenge, not only due to concerns about "drug-seeking", but because they have increased sensitivity to pain, a phenomenon identified as opioid-induced hyperalgesia (OIH). In an effort to improve pain treat...
What is the current status of trial NCT01210066?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2010-07. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01210066?
The interventions under investigation include: Cold pressor test (OTHER), Fentanyl (DRUG), Fentanyl plus cold pressor test (OTHER).
Who is sponsoring clinical trial NCT01210066?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01210066's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia